Document Detail


Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.
MedLine Citation:
PMID:  23543207     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Glioblastoma is the most common aggressive, highly glycolytic, and lethal brain tumor. In fact, it is among the most commonly diagnosed lethal malignancies, with thousands of new cases reported in the United States each year. Glioblastoma's lethality is derived from a number of factors including highly active pro-mitotic and pro-metastatic pathways. Two factors increasingly associated with the intracellular signaling and transcriptional machinery required for such changes are anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor (HGFR or, more commonly MET). Both receptors are members of the receptor tyrosine kinase (RTK) family, which has itself gained much attention for its role in modulating mitosis, migration, and survival in cancer cells. ALK was first described as a vital oncogene in lymphoma studies, but it has since been connected to many carcinomas, including non-small cell lung cancer and glioblastoma. As the receptor for HGF, MET has also been highly characterized and regulates numerous developmental and wound healing events which, when upregulated in cancer, can promote tumor progression. The wealth of information gathered over the last 30 years regarding these RTKs suggests three downstream cascades that depend upon activation of STAT3, Ras, and AKT. This review outlines the significance of ALK and MET as they relate to glioblastoma, explores the significance of STAT3, Ras, and AKT downstream of ALK/MET, and touches on the potential for new chemotherapeutics targeting ALK and MET to improve glioblastoma patient prognosis.
Authors:
Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Related Documents :
17012797 - Cloning, purification and preliminary crystallographic analysis of a putative pyridoxal...
24101047 - Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lu...
590237 - Action of adenosine hosphates on the release of intracellular lactate dehydrogenase fro...
24005867 - Role of cmet in the development and progression of colorectal cancer.
22330067 - Activation of p38 mapk by oxidative stress underlying epirubicin-induced vascular endot...
1009117 - Nucleotide specificity of pyruvate kinase and phosphoenolpyruvate carboxykinase.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-2
Journal Detail:
Title:  Metabolic brain disease     Volume:  -     ISSN:  1573-7365     ISO Abbreviation:  Metab Brain Dis     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610370     Medline TA:  Metab Brain Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Neurosciences and MUSC Brain & Spine Tumor Program, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An extreme test of mutational meltdown shows mutational firm up instead.
Next Document:  Purification and characterization of a dehalogenase from Pseudomonas stutzeri DEH130 isolated from t...